FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to crystalline modifications: 1 (polymorphous form F), 2 (polymorphous form I) and 3 (polymorphous form X) of monosodium salt of D-isoglytamyl-D-tryptophan (1:1) characterised by powder X-ray pattern peaks presented in the application materials, as well as to pharmaceutical compositions containing them. The invention describes their use for treating various diseases and body conditions of at least one autoimmune diseases specified in a group consisting of psoriasis, atopic dermatitis and rheumatoid arthritis.
EFFECT: present invention describes the methods for producing the declared crystalline modifications of monosodium salt of D-isoglytamyl-D-tryptophan (1:1).
42 cl, 4 ex, 9 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND MONOAMMONIUM SALT OF D-ISOGUTAMYL-D-TRYPTOPHAN | 2007 |
|
RU2483077C2 |
| PHARMACEUTICALLY ACCEPTABLE THYMODEPRESSIN SALTS AND METHOD OF OBTAINING THEREOF | 2007 |
|
RU2536685C2 |
| CRYSTALLINE ACYL-CHOLESTERIN ACYTRANSFERASE INHIBITOR | 2006 |
|
RU2394020C2 |
| SALTS AND POLYMORPHIC MODIFICATIONS OF THE INHIBITOR VEGF-R | 2006 |
|
RU2369607C1 |
| IBANDRONATE POLYMORPH B | 2006 |
|
RU2387661C2 |
| MACROCYCLIC POLYMORPHS, COMPOSITIONS CONTAINING SUCH POLYMORPHS, AND METHODS FOR USING AND PREPARING THEM | 2008 |
|
RU2478643C2 |
| TOPOTECAN MONOHYDROCHLORIDE PENTAHYDRATE IN CRYSTALLINE FORM, CORRESPONDING COMPOSITIONS BASED ON THEM, PREPARATION AND/OR TREATMENT METHODS | 2004 |
|
RU2352572C2 |
| NOVEL CRYSTALLINE FORM OF TRIAZOLO(4,5-d)PYRIMIDINE | 2005 |
|
RU2418802C2 |
| POLYMORPHIC MODIFICATION OF A IBANDRONATE | 2006 |
|
RU2368617C2 |
| METHOD OF PRODUCING MONOSODIUM SALT OF ISOGLUTAMYL-TRYPTOPHAN | 2019 |
|
RU2703991C1 |
